in vivo-jetPEI®

in vivo nucleic acid delivery

  • Suitable for in vivo delivery of any nucleic acid
  • Proven Track record: over 700 publications
  • Very easy to use: two-step protocol
  • Used for therapeutics and clinical trials worldwide
  • Safe: No inflammatory response triggered
  • Protocols tailored for your application by Polyplus-transfection delivery experts



in vivo-jetPEI®

Molecule delivered

DNA, siRNA, miRNA, Oligonucleotides, mRNA


in vivo functional studies
Cancer therapy
Genome editing

Targeted organs

All organs

Injection routes

Systemic delivery (Tail vein, intravenous, intraperitoneal injection)
Local injection

Number of transfections

100 µl of in vivo-jetPEI® delivery reagent is sufficient to perform 15 to 25 intravenous injections in mouse.


-20 °C, for at least 12 months

Provided with

10% glucose solution


in vivo-jetPEI® is a powerful polymer based reagent used to deliver any nucleic acid to any animal model. The protocol is similar to a classical transfection: the nucleic acid and the reagent are just mixed and administered to the animal.

in vivo-jetPEI® forms stable complexes with the nucleic acid, protecting it from degradation and thus facilitating in vivo delivery.

With a proven track record (over 700 Publications), in vivo-jetPEI® has already been used to target a wide range of organs using various administration routes.

Ordering information

Reference NumberAmount of reagentAmount of 10% glucose solution
201-10G0.1 ml10 ml
201-50G0.5 ml2 x 10 ml

Bulk quantities and GMP grade reagent are available upon request. Please contact us.

Request a quote

Suitable for in vivo delivery of any type of nucleic acid

in vivo-jetPEI® is the reagent of choice to deliver any type of nucleic acid (DNA, siRNA, miRNA, oligonucleotides and mRNA) to mediate gene expression or gene silencing in various tissues. The success of this delivery system relies on its ability to efficiently deliver the appropriate therapeutic nucleic acid into the target tissue or cells with low toxicity and limited immune response.

in vivo-jetPEI® is very versatile as it is suitable for the delivery of plasmid DNA (Fig. 1), siRNA (Fig. 2), shRNA, miRNA, oligonucleotides and mRNA.

<em>in vivo</em>-jetPEI - Protein expression following plasmid DNA systemic delivery

Fig. 1: Protein expression following plasmid DNA systemic delivery using in vivo-jetPEI®. Bioluminescent imaging of luciferase expression in living Nude mouse using IVIS 100 camera (Caliper-PerkinElmer) 24 h after gene delivery. pCMVLuc (50 µg) was complexed with in vivo-jetPEI® in 400 µl of 5% glucose solution and injected into the tail vein.


<em>in vivo</em>-jetPEI - siRNA mediated silencing of protein expression using <em>in vivo</em>-jetPEI<sup>®</sup> (control). <em>in vivo</em>-jetPEI - siRNA mediated silencing of protein expression using <em>in vivo</em>-jetPEI<sup>®</sup> (anti-luc).

Fig. 2: siRNA mediated silencing of protein expression using in vivo-jetPEI®. Bioluminescent imaging of luciferase expression in living nude mice using a cooled CCD camera 24 h after co-delivery of plasmid DNA and siRNA. pCMVLuc plasmid (50 µg) and 10 µg of siRNA (left panel: control siRNA; right panel: anti-luc siRNA) were complexed with in vivo-jetPEI® in 400 µl of 5% glucose solution and injected into the tail vein.

Easy two-step protocol

in vivo-jetPEI® is a very easy-to-use delivery reagent. The protocol consists in preparing the nucleic acid and reagent separately in 5% glucose solution, mixing them together and then, after a 15 min incubation time at room temperature, injecting the nucleic acid/ in vivo-jetPEI® complexes formed into animal (Fig. 3). This protocol is suitable for any administration route and any animal model.

<em>in vivo</em>-jetPEI - Protocol

Fig. 3: in vivo-jetPEI® protocol. Convenient protocol for delivery of any nucleic acid, using any route of administration in any animal model.

Wide range of administration routes

The stability of in vivo-jetPEI®/nucleic acid complexes allows the use of numerous routes of administration, including systemic or local injection, to target different organs (Fig. 4).

In vivo-jetPEI - Delivery routes
Fig. 4: Examples of delivery routes using in vivo-jetPEI in mice.

The route of administration largely determines the targeted organ. For example upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery (Fig. 5).

<em>in vivo</em>-jetPEI - Organs

Fig. 5: Organs targeted following systemic nucleic acid delivery using in vivo-jetPEI® in mice. pCMVLuc (50 µg) was complexed with in vivo-jetPEI® in 400 µl of 5% glucose solution and injected into the tail vein. 24 h after gene delivery, organs were extracted and luciferase level in each organ was analyzed using a luciferase assay and expressed relative to the amount of total proteins.

In addition to intravenous injection, in vivo-jetPEI® is also suitable for local delivery routes such as topical application, intracerebral or intra-articular injections, and it is perfect for nucleic acid delivery into subcutaneous tumor models.

Possible targeted organs include lungs, liver, brain, pancreas, spleen, kidney, heart, bladder, skin, retina, artery, etc.

Our delivery specialists are available to adapt our protocol to your specific application and send you the relevant literature (Please contact the technical support team at You may also download guidelines and protocols for in vivo experiments in mice, as well as technical notes containing publications with Polyplus-transfection® reagents sorted by administration route or by targeted organ/tissue (see in attached files button).

Suitable for any animal model

in vivo-jetPEI® is ideal for nucleic acid delivery in mice. However, the protocol is so easy and versatile that it has been adapted to many other species including rat, guinea pig, hamster, dog, rabbit, monkey, goat, sheep, cow, marmot, chicken, quail, duck, pigeon, gecko, tadpole, shrimp, zebrafish, abalone, snail, leech, mosquito…

Our delivery experts are available to adapt our protocol to your animal model and send you the relevant literature (Please contact the technical support team at

Currently used for therapeutics and clinical trials worldwide

in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. To fulfill all the quality requirements associated to the use of our reagent in Human, Polyplus-transfection® supplies preclinical grade reagents, as well as cGMP grade in vivo-jetPEI® that are currently used in several ongoing preclinical studies and phase I and II clinical trials (Fig. 6).

Fig. 6: Clinical pipeline of ongoing preclinical and clinical trials using in vivo-jetPEI®. in vivo-jetPEI® has been selected as a nucleic acid delivery vector for the development of a growing number of nucleic acid-mediated therapies. Type of nucleic acid delivered, administration route and therapeutic application are very diverse.

Safe: no inflammatory response triggered

Following in vivo-jetPEI® -mediated systemic delivery of nucleic acid, there is no induction of major pro-inflammatory cytokines and no increase in sera levels of hepatic enzymes (Bonnet et al. (2008), Pharm Res, 25:2972) (Fig. 6). Hence, in vivo-jetPEI® offers a reliable and safe alternative to viral vectors that can elicit an immune response.

<em>in vivo</em>- jetPEI - Inflammatory response
Fig. 7: No pro-inflammatory cytokine induced following intravenous delivery of nucleic acid/ in vivo-jetPEI® complexes. A siRNA (40 ug) was delivered with or without in vivo-jetPEI®. The level of TNF-α, IL12/IL23, IFNγ and IL6 was measured 1h, 6h, 12h and 6 h after delivery, respectively. The negative control is glucose only, the positive control is an IP injection of E. coli LPS (50 μg).

Stability of the nucleic acid/in vivo-jetPEI® complexes

Complexes formed between nucleic acids and in vivo-jetPEI® do not form aggregates over time and thus are stable for at least 24 h at RT, 4 °C and 37 °C (Fig. 8).

With stable complexes, the nucleic acid is protected for longer, thereby allowing the preparation of complexes in advance or the use of osmotic pumps for a continuous delivery.

<em>in vivo</em>-jetPEI - Complexe stability

Fig. 8: nucleic acid/in vivo-jetPEI® complexes are stable over time. pCMVLuc (40 µg) was complexed with in vivo-jetPEI®. Complexes incubated for 30 min or 24 h at 4 °C were intravenously injected. Bioluminescent imaging of the animals was performed using IVIS100 bioimaging system (Caliper-PerkinElmer) 24 h after injection.

For more details, please download the Bioimaging Application Note in Attached Files button.


If you have any questions regarding in vivo-jetPEI®, please visit our dedicated Frequently asked questions or contact us at

in vivo functional studies

in vivo-jetPEI® is perfectly suited to study gene function in vivo and provides the easiest method for the validation of in vitro functional studies into animals.

Read more…

Cancer Therapy

in vivo-jetPEI®-based nucleic acid delivery is now widely used for tumor growth inhibition studies. As an example, the delivery of a modified siRNA against Cyclin B1 with in vivo-jetPEI® inhibits the formation of lung metastases (Fig. 9A) and in vivo-jetPEI® mediated delivery of a modified siRNA against Survivin prevents the growth of a tumor xenograft model (Fig. 9B).

<em>in vivo</em>-jetPEI - Cancer therapy
Fig. 9: Tumor growth inhibition following in vivo-jetPEI® mediated delivery of modified siRNAs. (A) Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated intravenously with 1 mg/kg of STICKY siRNA™ against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90. (B) Mice bearing tumor xenografts were treated intravenously with 1 mg/kg of STICKY siRNA™ against Survivin (N/P=12.5). Tumor growth was monitored after each treatment and represented as a mean tumor volume ± SEM. Data from Kedinger et al., (2013), BMC Cancer 13:338.

Read more…


Following in vivo administration of plasmid DNA formulated with in vivo-jetPEI®, the expressed protein can elicit the induction of a robust and persistent immune response, hence protecting animals from different viruses or pathogens challenge.

Read more…

 in vivo gene editing using CRISPR/Cas9 system

in vivo-jetPEI®-mediated delivery of CRISPR/Cas9 system targeting tumor suppressor genes provides a flexible and effective method to investigate somatic loss-of-function alterations and their influence on tumorigenesis.

Read more…

Here is a selection of relevant references using in vivo-jetPEI®, more are available in our Polyplus-transfection Database.

Acosta, C., Djouhri, L., Watkins, R., Berry, C., Bromage, K., Lawson, S. N. (2014). TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain., J Neurosci 34, 1494-509.

Bivas-Benita, M., Gillard, G. O., Bar, L., White, K. A., Webby, R. J., Hovav, A. H., Letvin, N. L. (2013). Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity., Mucosal Immunol 6, 156-6.

Ellermeier, J., Wei, J., Duewell, P., Hoves, S., Stieg, M. R., Adunka, T., Noerenberg, D., Anders, H. J., Mayr, D., Poeck, H., Hartmann, G., Endres, S., Schnurr, M. (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer., Cancer Res 73, 1709-20.

Wahlquist, C., Jeong, D., Rojas-Munoz, A., Kho, C., Lee, A., Mitsuyama, S., van Mil, A., Park, W. J., Sluijter, J. P., Doevendans, P. A., Hajjar, R. J., Mercola, M. (2014). Inhibition of miR-25 improves cardiac contractility in the failing heart., Nature 508, 531-5.

Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C.B., Zapatka, M., Northcott, P.A., Schramm, K., Belic, J., Jones, D.T.W., Tschida, B., Moriarity, B., Largaespada, D., Roussel, M.F., Korshunov, A., Reifenberger, G., Pfister, S.M., Lichter, P., Kawauchi, D. and Gronych, J. (2015). Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling., Nat Commun 6:7391.

« I finished the experiments and I think in vivo-jetPEI® works great. I am very pleased with the results. Actually some of the work we have done with in vivo-jetPEI® as well as jetSI 10 mM has been published in Science. […] I am also very pleased with the technical assistance. Many thanks! » – Emine E.K., Hacettepe University, Turkey

g« Our project is going quite well, we are working a lot with your siRNAs delivery system, and we are obtaining superb results in vivo. » – Mattia C., L’Aquila University, Italy

g« in vivo-jetPEI® is a very nice reagent to work with! » – Marie-Line G., Lady Davis Institute, Canada

“I got a satisfied result with vivo-jetPEI® transfection agent to deliver microRNA mimics in rat uterus. And I appreciate the Polyplus team for their valuable support and help” – Rohit K., Texas A&M College of Veterinary Medicine, USA

Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.

Each lot of in vivo-jetPEI® is validated by DNA (pCMV-Luciferase) delivery into mouse through intravenous injection. The amount of luciferase (ng) per mg of protein is indicated on the certificate of analysis for each lot of reagent. Moreover, absence of endotoxin is verified in every lot of in vivo-jetPEI®.